A prospective study of monitoring practices for metabolic disease in antipsychotic-treated community psychiatric patients

Mackin, Paul; Bishop, David R.; Watkinson, Helen M. O.
January 2007
BMC Psychiatry;2007, Vol. 7, p28
Academic Journal
Background: Patients with severe mental illness are at increased risk for metabolic and cardiovascular disease. A number of recent guidelines and consensus statements recommend stringent monitoring of metabolic function in individuals receiving antipsychotic drugs. Methods: We conducted a prospective cohort study of 106 community-treated psychiatric patients from across the diagnostic spectrum from the Northeast of England to investigate changes in metabolic status and monitoring practices for metabolic and cardiovascular disease. We undertook detailed anthropometric and metabolic assessment at baseline and follow-up, and examined clinical notes and hospital laboratory records to ascertain monitoring practices. Results: A high prevalence of undiagnosed and untreated metabolic disease was present at baseline assessment. Mean follow-up time was 599.3 (SD ± 235.4) days. Body mass index (p < 0.005) and waist circumference (p < 0.05) had significantly increased at follow-up, as had the number of individuals who were either overweight or obese. Fifty-three per cent of individuals had hypertriglyceridemia, and 31% had hypercholesterolemia, but only 7% were receiving lipid-lowering therapy. Monitoring practices were poor. Recording of measures of adiposity occurred in 0% of individuals, and > 50% of subjects had neither blood glucose nor lipids monitored during the follow-up period. Conclusion: This cohort has a high prevalence of metabolic disease and heightened cardiovascular risk. Despite the publication of a number of recommendations regarding physical health screening in this population, monitoring rates are poor, and physical health worsened during the follow-up period.


Related Articles

  • The Impact of Blood Glucose and Cholesterol Levels on the Manifestation of Psychiatric Disorders. Owiredu, W. K. B. A.; Appiah-Poku, J.; Adusei-Poku, F.; Amidu, N.; Osei, Y. // Pakistan Journal of Biological Sciences;2009, Vol. 12 Issue 3, p252 

    This study examined possible association of fasting glucose and lipid abnormalities in psychiatric patients on conventional antipsychotic medications. A total of 305 subjects were used for the study, comprising 203 clinically diagnosed psychiatric patients and 102 non-psychiatric subjects used...

  • More Education, Dialogue Needed to Improve Side Effect Monitoring in Psychiatric Patients. Vinall, Maria // MD Conference Express;Jan2015, Vol. 14 Issue 44, p21 

    Psychiatric patients are often vulnerable physically, and studies show low rates of monitoring for side effects in patients taking second-generation antipsychotics (SGAs). This article discusses results of a study that used an online survey and interviews to investigate the barriers to...

  • Antipsychotic Drug Prescription in a Serbian Long-Stay Psychiatric Care Facility. Jankovic, S.M.; Kovacevic, Z.; Jankovic, S.V.; Kouvelas, D.; Papaioannidou, P.P.; Mirtsou-Fidani, V. // Clinical Drug Investigation;2001, Vol. 21 Issue 10, p679 

    Objective: This study evaluated the current use of antipsychotic drugs in a long-stay psychiatric care facility. Design and Setting: The study was a cross-sectional survey of drug therapy in a long-stay psychiatric care facility, performed in the Institute for Psychiatric Care of Adults in Male...

  • Neuroleptics in Psychiatric Inpatients: A Study from Western Development Region of Nepal. Banerjee, Indrajit; Roy, Bedanta; Sathian, Brijesh; Banerjee, Indraneel; Kumar, Prasanta; Chakraborty // Nepal Journal of Epidemiology;2014, Vol. 4 Issue 2, p6 

    An abstract of the article "Neuroleptics in Psychiatric Inpatients: A Study from Western Development Region of Nepal," by Indrajit Banerjee and colleagues is presented.

  • Metabolic monitoring of psychiatric patients on second-generation antipsychotics. Markopoulou, Maria; Georgiadou, Olga; Tsiftsoglou, Keranio; Bobotas, Konstantinos // Annals of General Psychiatry;2008 Supplement 1, Vol. 7, Special section p1 

    Background The current literature suggests that psychiatric patients have increased mortality and morbidity rates compared with the general population, primarily due to cardiovascular disease. There is increasing evidence that the use of second-generation antipsychotics is associated with an...

  • Metabolic monitoring in veterans with schizophrenia-related disorders and treated with second-generation antipsychotics: Findings from a Veterans Affairs-based population. Chienning Hsu; Ried, L. Douglas; Bengtson, Michael A.; Garman, Patrick M.; McConkey, Joel R.; Rahnavard, Farzad // Journal of the American Pharmacists Association: JAPhA;May/Jun2008, Vol. 48 Issue 3, p393 

    Objectives: To describe the proportions of veterans living with schizophrenia-related disorders monitored for dyslipidemia and hyperglycemia and to investigate whether the likelihood of metabolic dysregulation monitoring was influenced by veterans' sociodemographic characteristics, preswitch...

  • Bir Ãœniversite Hastânesinde Psikotik Bozukluk Hastalarında Atipik Antipsikotik Kullanımının Metabolik Etkileri. Cumurcu, Birgül Elbozan; Tümüklü, Mevhibe Nuray; Çelikel, Feryal Çam; Demir, Süleyman; Eğri, Mücahit // Yeni Symposium;2009, Vol. 47 Issue 4, p203 

    Objective: The aim of the study is to observe the metabolic side effects of atypical antipsychotic treatment in patients with psychotic disorders. Method: Patients with schizophrenia or any psychotic disorder [according to DSM-IV criteria], followed at the outpatient clinic of the Department of...

  • Prescribing Antipsychotics for Young People and Monitoring Physical Health and Adverse Effects. Ellis, David; Angley, Manya // Journal of Pharmacy Practice & Research;Sep2013, Vol. 43 Issue 3, p190 

    Background: Antipsychotics are increasingly prescribed in young people for psychiatric and behavioural disorders. Aim: To determine the appropriateness of antipsychotic prescribing in young people; to ascertain the usage of an antipsychotic monitoring program; and to determine congruence with...

  • Novel olanzapine analogues presenting a reduced H1 receptor affinity and retained 5HT2A/D2 binding affinity ratio. Jafari, Somayeh; Bouillon, Marc E.; Xu-Feng Huang; Pyne, Stephen G.; Fernandez-Enright, Francesca // BMC Pharmacology;2012, Vol. 12 Issue 1, p8 

    Background: Olanzapine is an atypical antipsychotic drug with high clinical efficacy, but which can cause severe weight gain and metabolic disorders in treated patients. Blockade of the histamine 1 (H1) receptors is believed to play a crucial role in olanzapine induced weight gain, whereas the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics